Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Novo Nordisk shares slide after weak 2026 guidance, while Eli Lilly rallies on strong earnings, booming weight loss drug sales, and a broader pipeline advantage.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 10% in the afternoon session after the company reported fourth-quarter 2025 results that beat Wall Street expectations and issued an upbeat forecast for 2026, driven by high demand for its weight-loss drugs.
Eli Lilly and Company (NYSE:LLY) reported fourth-quarter financial results on Wednesday. The transcript from the earnings call has been provided below.
Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is accepted.
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year revenue guidance of $81.5 billion at the midpoint came in 5.1% above analysts’ estimates. Its non-GAAP profit of $7.54 per share was 8.7% above analysts’ consensus estimates.
Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments.
Novo Nordisk stock sank as management forecasts decelerating growth in 2026. But should you treat this selloff in NVO shares as a buying opportunity? Let’s find out.
After more than three decades shaping global pharmaceutical manufacturing at industry leaders such as Jacobs, Worley, and CH2M Hill, Chinese engineer Ge Yang is drawing increasing attention from venture capital firms across Asia and the Middle East. Investors are eyeing his newly established life-science engineering startup, Stanhawk (Shanghai) Technology Co., Ltd.,which aims to redefine how vaccine, antibody, and gene therapy factories are designed and delivered worldwide.
